Search

Reset

Status

Medical Condition

Displaying 1 - 4 of 4

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML

Condition: Cancer / Leukemia
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This is a phase 1 study for participants with relapsed/refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) diagnosis. This study will observe the safety, side effects, and best dose of Imetelstat as an investigational drug, or drug that is not approved by the Food and Drug Administration (FDA…
Read More

Study of SL-172154 in Combination with PLD or MIRV in Patients with Ovarian Cancer

Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Closed
The purpose of this research study is to test the safety and determine the highest tolerable dose of SL-172154 (study drug) that can be given with Pegylated Liposomal Doxorubicin (PLD) or Mirvetuximab Soravtansine (MIRV). Another purpose of this study is to understand if SL-127154 and PLD or MIRV is effective in managing…
Read More

A study for patients acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm using study drug SL-401

Condition: Cancer / Leukemia
Investigator: Todd Rosenblat, MD
Status: Closed
The goal of this research study is to find the safest highest dose of SL-401 that can be given to patients with AML or BPDCN. This study will also look at how SL-401 stops or slows leukemia or BPDCN growth and how SL-401 enters and leaves the body. This study will also look at certain proteins in the …
Read More

Study of Upifitamab Rilsodotin (XMT-1536) in Patients with Recurrent Ovarian Cancer

Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
XMT-1536 (upifitamab rilsodotin) is a targeted therapy, which means that it is directed specifically at a tumor. It is a type of antibody-drug conjugate; this means it has 2 parts that are joined together into one drug. The first part is an antibody that binds to NaPi2b (sodium-dependent phosphate transporter), a protein on the surface of the cells of your…
Read More